12 September 2017

Invest in Skåne

Hosted by: Invest in Skåne

View session Description
NLSDays 2017 pre-event

MAX IV & ESS tour

10:00 - 14:00Bus Tour to Lund


View session Description

Academic Catwalk

17:00 - 18:15Main Hall

Nordic academic scientists will showcase intriguing research that could be the base for next generation therapies. The presentation will be followed by a short Q&A and is intended to give rise to inspiring discussions.

SmiLe Incubator
Johnson & Johnson Innovation

Hosted by: SmiLe IncubatorCo - Hosted by: Johnson & Johnson Innovation

View session Description

Startup Challenge @ NLSDays

18:30 - 20:00Main Hall

The Startup Challenge is a pitching competition giving innovative entrepreneurs an opportunity to showcase. Selected companies will present their innovative technologies to a selected jury representing life science executives from industry and finance.

13 September 2017


Hosted by: SwedenBIOCo - Hosted by: bionordic

Olivier Duchamp - Managing Director - NLSDays, CEO - Bionordic Services Jonas Ekstrand - Managing Director - SwedenBIO Mikael Dolsten - President Worldwide Research and Development and EVP - Pfizer

Lund University Diabetes Center
LU Innovation
Novo Nordisk

Hosted by: Lund University Diabetes CenterCo - Hosted by: LU Innovation, Novo Nordisk, Sanofi, Medeon

View session Description

Super Session 1 – Diabetes

09:30 - 10:45Plenary Room - Main Hall

The diabetes session will focus on disruptive new solutions and future diabetes treatment options. Special focus will be on recent developments , where closed loop systems and ultrafast acting insulins will be game changers for insulin treated diabetes patients, especially those with unstable blood glucose.

Moderator: Karin Hehenberger - CEO and Founder - Lyfebulb

Søren Bregenholt - Corporate VP and Head of External Innovation - Novo Nordisk Charlotte Ling - Professor, Lund University Uli Wendt - Head External Innovation and Alliance Management, Global Diabetes Division, R&D - Sanofi Annie Chandy - Innovation Manager - Lund University Diabetes Center Karin Hehenberger - CEO and Founder - Lyfebulb

Business Region Göteborg
Invest in Skåne

Hosted by: Business Region GöteborgCo - Hosted by: Invest in Skåne

View session Description

Super Session 2 – Regenerative Medicine

11:15 - 12:30Plenary Room - Main Hall

This supersession will focus on a specific field of regenerative medicine, Gene Therapy. The possibility to replace defective genes in a patient’s cells with healthy ones using viral vectors and gene editing technologies, opens up the potential to treat or prevent numerous diseases which currently lack successful treatment. Although most gene therapies are still in an experimental stage, several examples have recently been successfully translated into clinical practice and products with regulatory approval. This session will discuss the diverse challenges involved in the translation of gene therapies to clinic and market, and highlight some successful examples.

Steffen Thirstrup - Director Regulatory Advisory Board - NDA Reg Benjamin Schmid - Research Scientist, Disease Models - Bioneer Jukka Lausmaa - Research manager, Medical technology - RISE Sven Kili - Head of Cell & Gene Therapy Development - GSK Ralf Knöll - Chief Scientist - AstraZeneca Michael May - CEO - Center for Commercialization of Regenerative Medicine

Bjørg Nilsson - Senior Advisor - Norwegian Institute of Public Health Anders Hjelmencrantz - Partner and European Patent Attorney - Zacco


Hosted by: Vinnova

Sara Gunnerås - Director EU Support Office - SwedenBIO Elisabet Nielsen - EUREKA National Project Coordinator - Vinnova Inga Bruskeland - National Project Coordinator - Research Council of Norway Peter Lindberg - EUROSTARS Program Manager - Vinnova

Arthur D. Little

Hosted by: DNBCo - Hosted by: Arthur D. Little

View session Description
A new mechanism to fund the timely execution of lower-priority clinical trials

Super Session 4 – Financing of Phase 3 Studies

15:45 - 17:00Plenary Room - Main Hall

Some biopharma companies have built pipelines that offer more development opportunities than their resources allow them to pursue. Promising clinical trials may be moved down the priority list and their execution delayed – resulting in decline of asset value against a fixed patent expiration date. One potential solution is to package complementary trials and bring them into collaboration with investors, CROs or other organizations and fund the execution of these trials outside the biopharma company. There are several potential advantages of this approach. But this session will also reflect upon questions like: What would be the primary driving forces for different parties to engage in this type of collaborations? Are there also complications with the phenomenon? How does the excess of promising assets with large biopharma companies affect other parts of the life science ecosystem?

Moderator: Ulrica Sehlstedt - Partner - Arthur D. Little

Jo Sawyer - Head of External Partnerships - Novartis Ben van der Schaaf - Principal - Arthur D. Little Ulrica Sehlstedt - Partner - Arthur D. Little Johan Christenson - Partner - HealthCap Birgitte Volck - Vice President, Head of R&D Rare Diseases - GSK

Potter Clarkson

Hosted by: Potter Clarkson

Mats Grahn - CEO - Immunovia Olivier Laing - Senior Associate, IP Solicitor - Potter Clarkson Steve Smith - European Patent Attorney - Potter Clarkson

View session Description

Official Networking Reception at Copenhagen Papirhallen

18:00 - 22:00Copenhagen - Papirhallen

Papirhallen is an old paper warehouse in Copenhagen, updated with respect for the old and original look, offering unique atmosphere for creating a great networking experience.

14 September 2017


Hosted by: SwedenBIOCo - Hosted by: Covance

View session Description
Service providers as research power houses

Super Session 5 – Preclinical & Clinical Methodological Advancements

08:00 - 09:15Plenary Room - Main Hall

Many of the service providers in life science R&D have their own research. They provide much more than just an extra pair of hands and they spend high amounts on in house development of their services. With this super session, we will highlight their efforts and importance for the life science ecosystem where many of the companies are small and source for the latest technologies for their research and development.

Moderator: Christina Herder - CEO - Modus Therapeutics

Christina Herder - CEO - Modus Therapeutics Torkel Gren - Senior Sales Director, Development Services - Recipharm Sverre Bengtsson - CEO - Pharma Consulting Group Peter Varney - Marketing Head Early Development - Covance Michael Dabrowski - CEO - Pelago Bioscience

Bristol-Myers Squibb

Hosted by: AbbVieCo - Hosted by: Bristol-Myers Squibb

Moderator: Marianne Larsson - Innovation Director - Innovation Skåne

Amir Hefni - Country Manager - Bristol-Myers Squibb Marianne Larsson - Innovation Director - Innovation Skåne

Danish Agency for Science and Higher Education

Hosted by: VinnovaCo - Hosted by: Danish Agency for Science and Higher Education

View session Description
The innovative Medicines Initiative: speeding up medicines development through open research collaboration with the pharmaceutical industry

Workshop 3 – Innovative Medicine Initiative

09:30 - 10:45Room E

Research collaboration and funding opportunities for SMEs, Research Institutions, Hospitals and other stakeholders in the area of medicine development.

The Innovative Medicines Initiative (IMI2) is Europe’s largest public-private partnership in life science. It is jointly run and funded by the European Commission and the European Federation of Pharmaceutical Industries and Associations (EFPIA). Its aim is to improve the process of developing new drugs and treatments by supporting cooperation in research and development. IMI projects address such themes as preclinical and clinical methodological advancements, Digital Health, personalized medicine, Diabetes, Neurosciences and Oncology

The event is organized by VINNOVA , the Danish Agency for Science and Higher Education and The Research Council of Norway.

Who should join this session?
The workshop is an opportunity for a wide range of stakeholders – not least small and medium sized companies – to learn about the opportunities for R&D collaboration with the European pharmaceutical industry through IMI funded projects.  The workshop will highlight the experiences and learnings of Swedish and Danish IMI project participants from both industry and academia.


  • Welcome
  • Why IMI matters to Europe’s pharmaceutical industry
  • Advancing medicines development through open collaboration on research
  • Joining IMI – the SME  perspective
  • Joining IMI – The academic experience
  • Closing remarks

Magda Chlebus - Director of Science Policy - EFPIA Magali Poinot - Advisor and Legal Manager - IMI Joint Undertaking Peter Olofsson - CEO - Redoxis AB Poul Henning Jensen - Professor - Dept. Of Biomedicine, Aarhus University

Oslo Cancer Cluster

Hosted by: Oslo Cancer ClusterCo - Hosted by: DNB

View session Description
Advancing Cancer Immunotherapy by novel partnerships, bugs and bytes

Super Session 7 – Transformative Oncology

11:15 - 12:30Plenary Room - Main Hall

The session gathers a group of experts with complementary expertise to present and discuss recent approaches in Cancer Immunotherapy. Tremendous scientific progress resulted in real clinical breakthroughs and a growing number of cancers are now successfully treated with immunotherapy. However, many challenges remain and for tackling these collaborations among various disciplines is essential. A set of compact presentations will highlight how players from pharma, biotech and academia advance the field and what we can learn from microbiologists and machine learning experts.

Moderator: Benedicte Bakke - Senior Advisor, International Healthcare - DNB

Khatereh Ahmadi - Executive Director, Oncology Search and Evaluation Lead - MSD Per Norlèn - CEO -Alligator Bioscience Stefan Ries - Global Head of External Innovation, Oncology Discovery - pRED Roche Henrik Winther - Senior Vice President, Precision Diagnostics - Immunovia Benedicte Bakke - Senior Advisor, International Healthcare - DNB Jutta Heix - International Advisor - Oslo Cancer Cluster Richard Stratford - CEO - OncoImmunity

Invest in Skåne

Hosted by: Invest in Skåne

Moderator: Anna Sandström - Director Science Relations - AstraZeneca

Anna Sandström - Director Science Relations - AstraZeneca Anna Collen - Project Director Pharmaceutical Development - AstraZeneca

Life Science Nation

Hosted by: Life Science NationCo - Hosted by: Novo

View session Description
Best Practices for Identifying Capital in the Global Life Science Arena

Super Session 8 – Redefining Early Stage Investments

14:00 - 15:15Plenary Room - Main Hall

Early Stage Investments session provides a top-to-bottom master class on outbound global fundraising. Topics to be covered include the changing investor landscape, new categories of life science investors, and how to organize and execute a successful roadshow. It will bring you step-by-step through the processes of positioning, marketing collateral, website creation, branding & messaging, and how to reach out to a list of global investors.

Moderator: Dennis Ford - CEO - Life Science Nation

Dennis Ford - CEO - Life Science Nation Greg Mannix - VP International Business Development - Life Science Nation Colin Widen - CEO - Boston Innovation Capital Christopher De Souza - Director - Broadview Ventures Anna Danestig - Key Account Manager - PRV Yilmaz Mahshid - Investment Manager Life Science - Industrifonden

Nils Bohlin - Partner & Global Leader Healthcare - Arthur D. Little Jonas Ekstrand - Managing Director - SwedenBIO Olivier Duchamp - Managing Director - NLSDays, CEO - Bionordic Services